BioCorRx (BICX) Notes Payables (2010 - 2026)

BioCorRx has disclosed Notes Payables across 17 years of filings, most recently posting $1.2 million for Q1 2026.

• Notes Payables for Q1 2026 came in at $1.2 million, down 16.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 16.83% YoY), and the FY2025 annual result was $1.2 million, down 8.97% from the prior year.
• Notes Payables came in at $1.2 million for Q1 2026 at BioCorRx, up from $1.2 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $1.5 million in Q3 2025 to a low of $146426.0 in Q1 2024.
• The 5-year median for Notes Payables is $408238.0 (2023), against an average of $744606.9.
• Across the five-year window, Notes Payables sank 62.33% in 2022 and jumped 956.17% in 2025, its largest moves.
• BioCorRx's Notes Payables stood at $297602.0 in 2022, then surged by 103.88% to $606750.0 in 2023, then surged by 121.39% to $1.3 million in 2024, then dropped by 8.97% to $1.2 million in 2025, then increased by 1.37% to $1.2 million in 2026.
• The last three Notes Payables figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.